0000000000461843

AUTHOR

Gerardo Nardone

showing 21 related works from this author

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

2022

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 …

MaleCarcinoma HepatocellularCholestatic liver disease; Outcome; Surveillance; Survival; TreatmentSurveillanceHepatologySurvivalPrognosiLiver Cirrhosis BiliaryRisk FactorSettore MED/12 - GASTROENTEROLOGIALiver NeoplasmsGastroenterologyCholestatic liver diseasePrognosisTreatmentRisk FactorsHumansFemaleTreatment.HumanAgedOutcome
researchProduct

Identification of clinical phenotypes and related survival in patients with large hccs

2021

Background. Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. Aim. To examine patterns of tumor factors in large HCC patients. Methods. A database of large HCC patients was examined. Results. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin &gt

0301 basic medicineCancer Researchmedicine.medical_specialtyPVTSettore MED/12 - GASTROENTEROLOGIASerum albuminlcsh:RC254-282GastroenterologyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinePlateletHCCneoplasmsSurvival ratePVT.biologybusiness.industryProportional hazards modelAlbuminHazard ratioSettore MED/09 - MEDICINA INTERNAAlbuminMultifocalityHCC; large; phenotypes; PVT; multifocality; albuminlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseasesPortal vein thrombosisAlbumin; HCC; Large; Multifocality; Phenotypes; PVTPhenotypesPhenotype030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinLargebusiness
researchProduct

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interfer…

2016

none 48 no Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infec…

Liver CirrhosisMaleCirrhosisDatabases FactualGastroenterologyHCV-infected cirrhotic patients; hepatocellular carcinoma; HCC; sustained viral eradication; SVR; interferon0302 clinical medicineRetrospective StudiePharmacology (medical)Prospective StudiesHCV-infected cirrhotic patientsHCCProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCatheter AblationInterferon030211 gastroenterology & hepatologyFemaleLiver cancerHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularSVRLiver CirrhosiAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicinemedicineCarcinomaEarly Hepatocellular CarcinomaHumansAgedRetrospective StudiesAntiviral AgentHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryProspective Studiesustained viral eradicationInterferonsNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

2017

Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-relat…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularrecurrenceHepatitis C virusmedicine.medical_treatmentmedicine.disease_causesurvivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyhepatocellular carcinoma; prognosis; recurrences; survivalHumansSurvival analysisHepatologyrecurrencesbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseHepatitis Chepatocellular carcinoma; prognosis; recurrences; survival; Hepatology030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinoma030211 gastroenterology & hepatologyprognosisNeoplasm Recurrence LocalbusinessAdjuvantprognosi
researchProduct

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

2017

Background & Aims Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12Â months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. Methods A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BC…

Liver CirrhosisMaleHepatocellular Carcinoma Liver Cirrhosis hepatitis C virus Survival direct-acting antiviral agentsSurvival rateCirrhosisAntiviral agentGastroenterologyLiver cirrhosi0302 clinical medicineRecurrenceHepatic decompensation; Hepatitis C Virus (HCV); Hepatocellular carcinoma (HCC); Prognosis; Recurrences; Sustained virological response (SVR); overall survival (OS)Overall survivalLiver NeoplasmsHepatitis Coverall survival (OS)Middle AgedPrognosisHepatitis CSustained virological responseLocal030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; Aged; Carcinoma Hepatocellular; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards ModelsLiver cancerHepatic decompensationmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIA03 medical and health scienceshepatocellularInternal medicinemedicineEarly Hepatocellular CarcinomaHumansRecurrencesHepatocellular carcinoma (HCC)Survival rateAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; HepatologyAgedProportional Hazards ModelsHepatologybusiness.industryHepatitis C Virus (HCV)CarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesNeoplasm RecurrenceAntiviral agentsLiver cirrhosisLiver functionNeoplasm Recurrence LocalbusinessSustained virological response (SVR)
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

2019

Background: The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (ie tumour stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment selection and survival outcome in HCC patients. Patients and Methods: We analysed 4,867 consecutive HCC patients undergoing six main treatment strategies (liver transplantation, LT; liver resection, LR; ablation, ABL; intra-arterial therapy, IAT; Sorafenib, SOR; and best supportive care, BSC) and enrolled during 2002-2015 in a multicenter It…

MaleOncologySorafenibmedicine.medical_specialtyPrognostic variableCarcinoma Hepatocellularmedicine.medical_treatmenttreatment selectionLiver transplantationhepatocellular carcinoma; prognostic variable; survival benefit; treatment selection;03 medical and health sciencesprognostic variable0302 clinical medicineInternal medicinemedicineHumanssurvival benefithepatocellular carcinoma; prognostic variable; survival benefit; treatment selectionAgedNeoplasm StagingRetrospective StudiesAged 80 and overHepatologyPerformance statusbusiness.industryLiver NeoplasmsHazard ratiohepatocellular carcinomaMiddle Agedmedicine.diseaseConfidence intervalItaly030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyLiver cancerbusinessmedicine.drug
researchProduct

Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

2021

Background: Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation. Aims: To examine parameters of hepatocellular carcinoma aggressiveness as tumor size increases. Methods: A large hepatocellular carcinoma database was examined for trends in serum alpha-fetoprotein and the percentage of patients with macroscopic portal vein thrombosis or tumor multifocality. Results: A total of 13,016 hepatocellular carcinoma patients were identified having full tumor and survival data. Of these, 76.56% were mal…

MaleCancer ResearchPathologymedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIAClinical BiochemistrysizePathology and Forensic MedicineevolutionmedicineHumansProspective StudiesHCCTumor sizebusiness.industryLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularMiddle AgedPrognosismedicine.diseasePortal vein thrombosisHCC; evolution; size; trendtrendOncologyLiver NeoplasmHepatocellular carcinomaevolution; HCC; size; trendFemalebusinessHuman
researchProduct

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

2021

<b><i>Introduction:</i></b> The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times ac…

ALBI grade; Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; ITALICA staging system; MESIAHmedicine.medical_specialtylcsh:RC254-282GastroenterologyALBI gradeBarcelona Clinic Liver CancerInternal medicineMedicineIn patientCancer of the Liver Italian ProgramITALICA staging systemRadiologic ResponseSettore MED/12 - GastroenterologiaOriginal PaperHepatologybusiness.industryProportional hazards modelConfoundingHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMESIAHOncologyHepatocellular carcinomaAkaike information criterionbusinessLiver cancer
researchProduct

Rare-earth elements and yttrium distributions in mangrove coastal water systems: The western Gulf of Thailand

2005

The concentration of rare-earth elements and yttrium (REY) was investigated in dissolved phase, suspended particulate matter, and seafloor sediments of the western coastal area of the Gulf of Thailand. The samples show Eu and Gd positive anomalies in the shale-normalized REY patterns, especially in the suspended particulate matter. On the other hand, a very high REE content was detected in the coastal waters, probably due to the weathering produced by the Mae Klong river waters on rare-earth element (REE)-rich accessory minerals coming from terrains and mineral deposits cropping out in the studied area. The shale-normalized patterns of yttrium and REE estimated for the dissolved phase show …

MineralEcologySettore BIO/02 - Botanica SistematicaRare earthGeochemistrychemistry.chemical_elementSedimentWeatheringYttriumParticulatesRare-earth elements Gulf of Thailand Eu and Gd anomaliesSeafloor spreadingOceanographychemistryGeneral Earth and Planetary SciencesMangroveEcology Evolution Behavior and SystematicsGeologyGeneral Environmental ScienceChemistry and Ecology
researchProduct

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

2022

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…

Atezolizumab-bevacizumabClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCarcinoma HepatocellularSystemic therapyHepatologyHepatocellular carcinomaTirosin-kinase inhibitorLiver NeoplasmsGastroenterologyTirosin-kinase inhibitor.Atezolizumab-bevacizumab; Hepatocellular carcinoma; Systemic therapy; Tirosin-kinase inhibitorBevacizumabFeasibility StudieTyrosineHumanDigestive and Liver Disease
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

Heavy metals in coastal water systems. A case study from the northwestern Gulf of Thailand.

2005

A geochemical survey of the northwestern part of the Thailand Gulf (Inner Gulf) was carried out in order to define concentrations and distribution patterns of selected heavy metals (V, Cr, Co, Ni, Cu, Zn, and U) in the coastal system and estuarine area of the Mae Klong river. The results indicate the presence of two different sources of heavy metals in the studied environment and allowed us to identify a lithogenic component that significantly influences the composition of coastal waters and suspended particulate matter (SPM). Comparison of the normalized heavy metals concentrations both in the studied samples and in those reported for the Sn–W ores present in the surrounding areas suggests…

Geologic SedimentsEnvironmental EngineeringHealth Toxicology and MutagenesisMineralogyMetals HeavyEnvironmental monitoringWater Pollution ChemicalEnvironmental ChemistrySeawaterWater pollutiongeographygeography.geographical_feature_categoryPublic Health Environmental and Occupational HealthFlocculationEstuaryGeneral MedicineGeneral ChemistryParticulatesContaminationThailandTrace elements riverPollutionSeafloor spreadingEnvironmental chemistrySeawaterAdsorptionEnrichment factorEnvironmental MonitoringChemosphere
researchProduct

Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

2021

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient …

Liver CancerPre-TACE-Predict modelmedicine.medical_specialtybusiness.industryTrans-arterial chemoembolizationPharmaceutical Sciencehepatocellular carcinomamedicine.diseaseGastroenterologyComplementary and alternative medicineInternal medicineHepatocellular carcinomamedicinePharmacology (medical)Trans arterial chemoembolizationbusinessLiver Cancer International
researchProduct

Monofocal hepatocellular carcinoma: How much does size matter?

2020

Background & Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5 cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5 cm; SEM-HCC), 163 patients with larger tumours (>5 cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0 months; P…

medicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularIndependent predictorGastroenterologyResection03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHepatectomyHumansStaging systemNeoplasm StagingRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologytreatmentbusiness.industrySettore MED/09 - MEDICINA INTERNALiver Neoplasmsbclc staging systemmonofocal hepatocellular carcinomamedicine.diseasedigestive system diseasesSurvival benefitItaly030220 oncology & carcinogenesisHepatocellular carcinomabclc staging system; liver resection; monofocal hepatocellular carcinoma; prognosis; treatmentliver resection030211 gastroenterology & hepatologyprognosisbusinessLiver cancerprognosi
researchProduct

Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

2021

Abstract Aim This study investigated how material deprivation in Italy influences the stage of hepatocellular carcinoma (HCC) at diagnosis and the chance of cure. Methods 4114 patients from the Italian Liver Cancer database consecutively diagnosed with HCC between January 2008 and December 2018 were analysed about severe material deprivation (SMD) rate tertiles of the region of birth and region of managing hospitals, according to the European Statistics on Income and Living Conditions. The main outcomes were HCC diagnosis modalities (during or outside surveillance), treatment adoption and overall survival. Results In more deprived regions, HCC was more frequently diagnosed during surveillan…

Cancer Researchmedicine.medical_specialtySettore MED/12 - GastroenterologiaDeprivationbusiness.industryHepatocellular carcinomaPrognosiHazard ratioDeprivation; Hepatocellular carcinoma; Overall survival; Prognosis; Social determinants of healthmedicine.diseasePrognosisSocial determinants of healthOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalOverall survivalSocial determinants of healthStage (cooking)businessLiver cancerSocioeconomic status
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.

2006

Gastric adenomas are rare neoplastic growths characterized by localized polypoid proliferations of dysplastic epithelium that tend to progress to infiltrating adenocarcinoma. Therefore, the identification of molecular markers that could reliably recognize adenomas at risk of progression is advocated in the clinical management. In this study we investigated, in a series of gastric adenoma specimens from an area at high risk of gastric cancer, the relationship between clinicopathological characteristics of adenoma and Helicobacter pylori infection, APC mutational status, and COX-2 and the down-stream enzyme mPGES1 expression. Helicobacter pylori infection, detected in 24%, and 33% by histolog…

AdenomaMaleGenes APCAdenomaAdenocarcinomamedicine.disease_causegastric adenomaHelicobacter InfectionsHelicobacter pyloryStomach NeoplasmsmedicineHumansAPC mutationsAgedProstaglandin-E SynthasesAged 80 and overMutationbiologyHelicobacter pyloribusiness.industryCancerAPC mutations; COX-2; gastric adenoma; Helicobacter pyloriHistologyHematologyHelicobacter pyloriCOX-2Middle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesEpitheliumIntramolecular Oxidoreductasesmedicine.anatomical_structureOncologyDysplasiacyclooxygenase-2Cyclooxygenase 2Gastric MucosaMutationCancer researchAPC-mutations gastric adenoma Helycobacter pyloriAdenocarcinomaFemalebusiness
researchProduct

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

2021

Simple Summary Accurate prognostic systems capable of predicting the survival of patients with advanced hepatocellular carcinoma undergoing Sorafenib therapy are still lacking. The search for the ideal predictive tool for survival and drug response is justified by the recent availability of several other drugs effective for these patients, licensed as first- and second-line treatment, other than reducing adverse events and costs. In this study, we aimed to identify simple demographic and clinical parameters able to predict survival and Sorafenib response in a large multicenter cohort. In this study, we showed that patient’s general status, liver function and damage laboratory parameters and…

Cohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; SurvivalSorafenibOncologyCancer Researchmedicine.medical_specialtyPrognosisurvivalArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecohort studyRC254-282Settore MED/12 - GastroenterologiaPerformance statusProportional hazards modelbusiness.industryHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomaNomogrammedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologysorafenibprognosisLiver cancerbusinessmedicine.drugCancers
researchProduct

Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment

2022

BackgroundTransarterial chemoembolization (TACE) is one of the most frequently applied treatments for hepatocellular carcinoma (HCC) worldwide. In this study, we aimed at evaluating whether and how TACE application and repetition, as well as the related outcome, have changed over the last three decades in Italy.MethodsData of 7,184 patients with HCC were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. Patients were divided according to the period of diagnosis in six cohorts: P1 (1988–1993), P2 (1994–1998), P3 (1999–2004), P4 (2005–2009), P5 (2010–2014), and P6 (2015–2019). All the analyses were repeated in the overall patient population and in Barcelona Clinic Liver Cancer (BC…

Cancer ResearchOncologySettore MED/09 - MEDICINA INTERNAiterative treatmenthepatocellular carcinoma; iterative treatment; survival; therapeutic hierarchy; transarterial chemoembolizationtherapeutic hierarchyNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomatransarterial chemoembolizationsurvivalRC254-282
researchProduct